Holen Sie sich die Stockscreener-App
14.53
0.41%
0.06
Handel nachbörslich:
14.60
0.07
+0.48%
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Will ARS Pharmaceuticals Inc. Benefit From Sector TailwindsMarket Risk Analysis & Stepwise Trade Signal Implementation - newsyoung.net
ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - simplywall.st
ARS Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
ARS Pharmaceuticals Plunges 9.23%—What's Unraveling in the Lab? - AInvest
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales - Investing.com India
ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets - MSN
ARS Pharmaceuticals Reports Strong Growth for neffy - TipRanks
ARS Pharmaceuticals 2025 Q2 Earnings Sharp Revenue Surge Amid Widening Losses - AInvest
ARS Pharmaceuticals shares rise 1.07% after-hours after reporting Q2 revenue of $15.7 million and global expansion of neffy. - AInvest
ARS Pharma Sales Jump 3,040% in Q2 - The Motley Fool
ARS Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals' Q2 2025: Navigating Key Contradictions in DTC Impact, Inventory, and NUCLEUS Commercialization - AInvest
ARS Pharmaceuticals reports reports Q2 EPS (46c), consensus (51c) - TipRanks
SPRY Plummets 11.5%: What's Behind the Sharp Decline? - AInvest
Transcript : ARS Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
ARS Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q2 2025 revenue beats forecast - Investing.com
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises - MarketScreener
ARS Pharmaceuticals earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
ARS Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q2 Revenue $15.7M, vs. FactSet Est of $13.8M - MarketScreener
ARS Pharmaceuticals Reports Second Quarter 2025 Financial - GlobeNewswire
ARS Pharmaceuticals Posts $15.7 Million Q2 Revenue, Neffy Sales Reach $12.8 Million in US. - AInvest
ARS Pharma (SPRY) 8-K: Q2 Results & Updated Investor Presentation Filed | SPRY SEC FilingForm 8-K - Stock Titan
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) - Yahoo Finance
TR | OpenAI4o Maintains ARS Pharmaceuticals(SPRY.US) With Hold Rating, Cuts Target Price to $16.5 - 富途牛牛
What drives ARS Pharmaceuticals Inc.’s stock priceShort-Term Explosive Growth - 선데이타임즈
What ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) 26% Share Price Gain Is Not Telling You - 富途牛牛
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
ARS Pharmaceuticals SPRY 2025Q2 Earnings Preview Upside Potential Amid Strategic Developments - AInvest
What are the risks of holding ARS Pharmaceuticals Inc.Maximum Return Portfolio Ideas - thegnnews.com
ARS Pharmaceuticals: Pioneering a Needle-Free Revolution in Allergy Treatment - AInvest
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewswire
ARS Pharmaceuticals to discuss Q2 2025 financial results Aug 13. - AInvest
ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results - Stock Titan
What drives ARS Pharmaceuticals Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
How volatile is ARS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms the market - Jammu Links News
How does ARS Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What institutional investors are buying ARS Pharmaceuticals Inc. stockMarket-beating returns - Jammu Links News
Is ARS Pharmaceuticals Inc. a growth stock or a value stockMassive portfolio appreciation - Jammu Links News
What analysts say about ARS Pharmaceuticals Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
Is ARS Pharmaceuticals Inc. stock overvalued or undervaluedBuild a portfolio that grows with the market - Jammu Links News
What makes ARS Pharmaceuticals Inc. stock price move sharplyHigh-profit capital plays - Jammu Links News
How does ARS Pharmaceuticals Inc. generate profit in a changing economyMarket-crushing stock picks - Jammu Links News
How strong is ARS Pharmaceuticals Inc. company’s balance sheetTriple-digit profit margins - Jammu Links News
Does ARS Pharmaceuticals Inc. stock perform well during market downturnsStay ahead with advanced stock screening tools - Jammu Links News
What is the risk reward ratio of investing in ARS Pharmaceuticals Inc. stockGet expert alerts on market-moving stocks - Jammu Links News
ARS Pharmaceuticals Inc. Stages Intraday Comeback — Trend ChangeConservative Long Term Growth Plans Under Review - beatles.ru
What are ARS Pharmaceuticals Inc. company’s key revenue driversDaily Trading Strategy For Smart Trading - jammulinksnews.com
What is ARS Pharmaceuticals Inc. company’s growth strategyBreakout Stocks Watchlist That Work - jammulinksnews.com
Why is ARS Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Picks With High Returns - Jammu Links News
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength - Yahoo Finance
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):